Integrated Metabolic Oncology: A Systems-Based Framework for Overcoming Therapeutic Resistance Using Repurposed Agents and Orthomolecular Protocols

By Editorial Team
Abstract: Therapeutic resistance remains the primary cause of cancer-related mortality, driven by cancer cells' extraordinary metabolic plasticity and ability to remodel the tumor microenvironment. While traditional precision oncology focuses on genomic drivers, emerging evidence suggests that a multidimensional approach—integrating metabolism, immunity, and evolutionary selection pressures—is required for durable control. This article explores the Personalized Metabolic Oncology (PMO) framework and the Hybrid Orthomolecular Protocol, which utilize repurposed antiparasitic agents like ivermectin, fenbendazole, and mebendazole to target the mitochondrial-stem cell connection and metabolic vulnerabilities. By "stacking" evidence-based interventions including dietary modulation, orthomolecules, and repurposed drugs, clinicians can address cancer as a dynamic adaptive ecosystem.

Keywords: Personalized Metabolic Oncology, Ivermectin, Fenbendazole, Therapeutic Resistance, Cancer Stem Cells, Drug Repurposing, Immunometabolism.

1. Introduction: The Crisis of Therapeutic Resistance

Despite advances in targeted and immunotherapies, aggressive tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma frequently develop resistance. The high cost of oncology drugs—exceeding $150 billion globally—and slow approval rates have spurred interest in drug repurposing. This strategy identifies new uses for established, low-cost drugs to accelerate treatment access while reducing safety risks.

2. Mechanisms of Repurposed Antiparasitic Agents

Repurposed agents like fenbendazole, mebendazole, and ivermectin exert multi-targeted anticancer effects by disrupting survival pathways that standard therapies often miss.

  • Fenbendazole (FBZ): A benzimidazole that destabilizes microtubules, induces G2/M cell cycle arrest, and impairs glucose metabolism by inhibiting GLUT1/4 transporters and hexokinase activity. It effectively "starves" cancer cells of energy.
  • Mebendazole (MBZ): Structurally related to FBZ but with better human bioavailability, MBZ disrupts microtubule polymerization and has shown synergy with tyrosine kinase inhibitors. It is capable of crossing the blood-brain barrier, making it a candidate for brain tumor protocols.
  • Ivermectin (IVM): A macrocyclic lactone that inhibits oncogenic pathways (STAT3, Wnt/β-catenin, AKT/mTOR), targets cancer stem cells (CSCs), and induces mitochondrial dysfunction. Preclinical studies show efficacy in over 20 cancer types.

3. The Personalized Metabolic Oncology (PMO) Framework

The PMO framework shifts the focus from "What mutation does this tumor have?" to "How does this tumor survive?". It involves a four-step precision process:

  1. Molecular Characterization: Using whole exome and RNA sequencing to identify genomic context.
  2. Metabolic Phenotyping: Identifying dominant energy pathways (glycolysis vs. OXPHOS) using biomarkers like fasting insulin, lactate, and ketone levels.
  3. Immune Profiling: Evaluating the tumor microenvironment (TME) and PD-L1 expression to understand metabolic immune suppression.
  4. Therapeutic Personalization: Integrating standard care with metabolic strategies like carbohydrate restriction and repurposed modulators.

4. The 7-Layer Evidence-Based Stacking Strategy

The Metabolic Cancer Framework 2026 proposes a rational "stacking" model to create a systemic "metabolic headwind" against progression:

Layer Strategy Rationale
1 Metabolic Modulation Targets glycolysis and mitochondria to reduce biomass synthesis.
2 Tumor-Directed Therapy Standard care (Surgery, Radiation, Chemotherapy, Immunotherapy, Targeted Therapy).
3 Immune Optimization Restores T-cell function by reducing lactate-induced suppression.
4 Microbiome Support Enhances immunotherapy response through gut health.
5 Adjunct Therapies Repurposed drugs (IVM/MBZ) and natural compounds (Curcumin).
6 Dietary Strategies Ketogenic diets or fasting to lower insulin and IGF-1 signaling.
7 Lifestyle Optimization Physical activity and sleep to reduce chronic inflammation.

5. The Hybrid Orthomolecular Protocol

A specific peer-reviewed protocol targets the mitochondrial-stem cell connection (MSCC), suggesting cancer arises from chronic oxidative phosphorylation (OxPhos) insufficiency in stem cells. Key recommendations include:

  • Intravenous Vitamin C: Non-toxic pro-oxidant therapy (1.5g/kg/day).
  • High-Dose Vitamin D: Targeting blood levels of 80 ng/mL to support immune function.
  • Zinc Supplementation: Maintained at 80 to 120 μg/dL.
  • Aggressive Repurposed Dosing: For high-grade "turbo" cancers, ivermectin doses may reach 1-2 mg/kg/day, and fenbendazole may be dosed up to 1,000 mg 3x per week.

6. Challenges and Future Directions

While case reports and preclinical data are compelling—with some series documenting responses in over 700 patients—large-scale randomized controlled trials (RCTs) are lacking due to the low-cost, off-patent nature of these drugs. Researchers advocate for N=1 trials and real-world data analysis to refine personalized protocols.

Conclusion

Cancer is a complex adaptive system, not just a genetic disease. Integrating metabolic and orthomolecular strategies with conventional oncology offers a robust pathway to overcome resistance. Future care must focus on hope + evidence, layering validated strategies to maximize both effectiveness and safety.

References:

  1. Baghli I, et al. (2024). Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol. J Orthomol Med. 39.3.
  2. OneDayMD. (2026). The Metabolic Cancer Framework 2026: A 7-Layer Evidence-Based Stacking Strategy.
  3. OneDayMD. (2026). Personalized Metabolic Oncology: A Precision Framework for Overcoming Cancer Resistance.
  4. OneDayMD. (2026). Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments.
  5. OneDayMD Editorial Team. Fenbendazole, Ivermectin and Mebendazole for Cancer: Case Series of 767 Case Reports. The Medical Advisor, OneDayMD.com. May 2026. https://www.onedaymd.com/2024/02/fenbendazole-cancer-success-stories.html
  6. Hulscher N et al. Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort. Anticancer Research Jun 2026, 46 (6) 3243-3255; DOI: 10.21873/anticanres.18194

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

By Editorial Team
Image
Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. Supporters point to hundreds of preclinical studies and case reports showing anti-tumor activity across multiple cancer types.  However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiotherapy. So where does the truth lie? The answer is more nuanced than either side often suggests. Access to modern cancer care remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings m...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 700 Patients (2026)

By Editorial Team
Image
Medically Reviewed by: OneDayMD Editorial Team | Last Updated: May 2026 Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Table of Contents: Editor's Preface Introduction Fenbendazole and Iverme...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. There are presently over 1,500 herbs and food supplements in commerce, many of them with claims in use against cancer. This guide compiles over 500 scientific r...
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2026)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

By Editorial Team
Image
Dr. William Makis, a radiologist and cancer researcher, has developed a "hybrid orthomolecular" protocol that incorporates ivermectin as a repurposed drug for cancer treatment. This approach targets cancer stem cells and mitochondrial dysfunction, often in combination with other therapies like benzimidazoles (e.g., mebendazole or fenbendazole), vitamins, and dietary changes. The protocol is based on preclinical studies, case reports, and his clinical observations, but it remains experimental and unapproved by regulatory bodies like the FDA for cancer use. Dosages are weight-based (e.g., for a 70 kg/154 lb person, 1 mg/kg = 70 mg) and stratified by cancer severity: low-grade (early-stage or slow-growing), intermediate-grade (moderately progressive), or high-grade (aggressive, metastatic, or "turbo" cancers). Always consult a healthcare provider for personalization, monitoring (e.g., liver/kidney function), and integration with conventional treatments. Key Ivermectin...
Read more

Fenbendazole and Ivermectin for Stage 4 Pancreatic Cancer: A Compilation of Case Reports and Mechanistic Insights (2026)

By Editorial Team
Image
Summary Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited effective therapies and poor survival, especially in stage 4 disease. Repurposing antiparasitic agents such as fenbendazole and ivermectin has garnered interest due to their demonstrated anti-cancer properties in preclinical studies. Methods: We reviewed and synthesized 35 detailed case reports from 2022 to 2026 documenting the clinical use of fenbendazole and ivermectin, alone or in combination with standard therapies, in patients with advanced pancreatic cancer. Tumor markers, imaging outcomes, and clinical responses were analyzed alongside mechanistic literature. Results: Across cases, patients exhibited marked reductions in CA19-9 tumor markers (often >70%), significant tumor shrinkage on imaging, and improved clinical status. Responses were observed even in chemotherapy-resistant and metastatic disease. Mechanistic studies support multiple anti-cancer effects of...
Read more

Archive

Show more